Literature DB >> 2598171

Pharmacokinetic studies of radiolabelled rat monoclonal antibodies recognising syngeneic sarcoma antigens. II. Effect of host age and immune status.

S A Eccles1, H P Purvies, J M Styles, S M Hobbs, C J Dean.   

Abstract

In the preceding paper it was suggested that the tumour localisation of 125I-labelled syngeneic rat monoclonal antibodies (mAbs) may be limited in immunocompetent hosts by the presence of competing endogenous serum antibodies. In syngeneic congenitally athymic (nu/nu) and cyclosporin-A-treated rats (both of which fail to mount immune responses to tumour antigens) increased uptake of mAbs in tumour tissue was obtained compared with that in immunocompetent animals. However, in the case of IgG2b and IgG1 mAbs, this appeared to be due primarily to enhanced "non-specific" localisation mediated by Fc binding, since it was abolished by the use of F(ab')2 fragments with two out of three mAbs tested. Normal tissue distribution was also influenced by host immune status: in nu/nu rats the uptake of IgG2b mAbs in the spleen was up to fivefold higher than that previously found in normal animals and the levels in liver were also increased. This effect was not seen in cyclosporin-A-treated hosts, suggesting that the reticuloendothelial system of congenitally athymic animals contains cells with enhanced IgG2b-FcR activity. This hypothesis was strengthened by the observation that splenic uptake was reduced by either the use of F(ab')2 fragments, or prior "blockade" of Fc receptors by "cold competition" with excess unlabelled IgG2b mAbs. This blockade could not be effected by mAbs of any other isotype or by IgG2b F(ab')2 fragments. The former manoeuvre resulted in higher tumour specificity ratios but usually at the expense of reduced levels of tumour associated radiolabelled mAb. The latter was found to increase "absolute" tumour localisation by up to 35%. In an attempt to characterise further and compare the Fc receptor activity of intratumour and intrasplenic host cells. The distribution of IgG2b mAbs was assayed in 3-week, 8-week and 12-week-old rats. We were able operationally to distinguish the activity of these two categories of cells, suggesting that they represent either different lineages or differentially activated subpopulations: the splenic IgG2b binding was fully expressed in weanling nu/nu rats whereas the FcR activity of cells infiltrating MC24 sarcoma was limited in 3-week-old compared with 8-12-week-old hosts. A further difference was apparent in the subclass "preference" of FcR binding: in immunodeprived rats both IgG1 and IgG2b mAbs were able to bind to tumour-infiltrating host cells, but uptake of IgG1 mAbs in the spleen was always low and not reduced further by the use of F(ab')2 fragments.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2598171     DOI: 10.1007/bf01665025

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  15 in total

Review 1.  Basic principles and applications of monoclonal antibodies in the management of carcinomas: the Richard and Hinda Rosenthal Foundation award lecture.

Authors:  J Schlom
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

2.  The regulation of macrophage activity in congenitally athymic mice.

Authors:  A K Sharp; M J Colston
Journal:  Eur J Immunol       Date:  1984-01       Impact factor: 5.532

3.  Imaging of human tumor xenografts in nude mice with radiolabeled monoclonal antibodies. Limitations of specificity due to nonspecific uptake of antibody.

Authors:  B D Mann; M B Cohen; R E Saxton; D L Morton; W F Benedict; E L Korn; L Spolter; L S Graham; C C Chang; M W Burk
Journal:  Cancer       Date:  1984-10-01       Impact factor: 6.860

4.  Imaging of melanoma with L-131-labeled monoclonal antibodies.

Authors:  S M Larson; J P Brown; P W Wright; J A Carrasquillo; I Hellström; K E Hellström
Journal:  J Nucl Med       Date:  1983-02       Impact factor: 10.057

5.  Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab')2 fragments.

Authors:  G L Buraggi; L Callegaro; G Mariani; A Turrin; N Cascinelli; A Attili; E Bombardieri; G Terno; G Plassio; M Dovis
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

6.  Pharmacokinetics of 111In-labeled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma.

Authors:  M G Rosenblum; J L Murray; T P Haynie; H J Glenn; M F Jahns; R S Benjamin; J M Frincke; D J Carlo; E M Hersh
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

7.  Radioimmunoimaging in malignant melanoma with 111In-labeled monoclonal antibody 96.5.

Authors:  J L Murray; M G Rosenblum; R E Sobol; R M Bartholomew; C E Plager; T P Haynie; M F Jahns; H J Glenn; L Lamki; R S Benjamin
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

8.  Macrophage activation selectively enhances expression of Fc receptors for IgG2a.

Authors:  R A Ezekowitz; M Bampton; S Gordon
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

9.  Metastasis in the nude rat associated with lack of immune response.

Authors:  S A Eccles; J M Styles; S M Hobbs; C J Dean
Journal:  Br J Cancer       Date:  1979-11       Impact factor: 7.640

10.  Effect of cyclosporin A on the growth and spontaneous metastasis of syngeneic animal tumours.

Authors:  S A Eccles; S E Heckford; P Alexander
Journal:  Br J Cancer       Date:  1980-08       Impact factor: 7.640

View more
  4 in total

1.  Monoclonal antibodies for the treatment of metastases. Evaluation of strategies using a syngeneic rat model.

Authors:  S A Eccles; G Box; W Court; M K Collins; C J Dean
Journal:  Cell Biophys       Date:  1993 Jan-Jun

Review 2.  Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?

Authors:  S A Eccles
Journal:  Breast Cancer Res       Date:  2000-12-20       Impact factor: 6.466

3.  Spectroscopic Photoacoustic Molecular Imaging of Breast Cancer using a B7-H3-targeted ICG Contrast Agent.

Authors:  Katheryne E Wilson; Sunitha V Bachawal; Lotfi Abou-Elkacem; Kristen Jensen; Steven Machtaler; Lu Tian; Jürgen K Willmann
Journal:  Theranostics       Date:  2017-04-03       Impact factor: 11.556

4.  Ultrasound molecular imaging as a non-invasive companion diagnostic for netrin-1 interference therapy in breast cancer.

Authors:  Jennifer Wischhusen; Katheryne E Wilson; Jean-Guy Delcros; Rodolfo Molina-Peña; Benjamin Gibert; Shan Jiang; Jacqueline Ngo; David Goldschneider; Patrick Mehlen; Juergen K Willmann; Frederic Padilla
Journal:  Theranostics       Date:  2018-10-06       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.